Zai Lab Ltd.
Latest From Zai Lab Ltd.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
- Medical Devices
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- ZAI Laboratory Inc.
- Parent & Subsidiaries
- Zai Lab Ltd.
- Senior Management
Samantha Du, PhD, Chmn. & CEO
Billy Cho, CFO
Jonathan Wang, SVP, Head, Bus. Dev.
William Liang, Chief Commercial Officer
Tao Fu, Pres. & COO
- Contact Info
Zai Lab Ltd.
Phone: 21 6163 2588
4560 Jinke Rd., Jinchuang Plaza Bldg. 1
Pudong, Shanghai, 201210
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.